Integra LifeSciences (NASDAQ:IART) Updates FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.400-2.500 for the period, compared to the consensus earnings per share estimate of 2.350. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q2 2026 guidance to 0.440-0.520 EPS.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Finally, Citigroup decreased their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $14.80.

Integra LifeSciences Trading Up 3.2%

IART stock traded up $0.43 during midday trading on Wednesday, reaching $13.65. 365,445 shares of the company’s stock traded hands, compared to its average volume of 811,868. The company has a market capitalization of $1.06 billion, a P/E ratio of -2.02 and a beta of 1.08. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The business has a 50-day moving average price of $10.11 and a two-hundred day moving average price of $11.73.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period in the previous year, the company posted $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts forecast that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — quarterly EPS of $0.54 topped consensus ~$0.41 and revenue of ~$392M exceeded estimates, showing modest growth versus year‑ago figures. Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Full‑year EPS guidance raised to $2.40–$2.50, above consensus (~$2.35), giving longer‑term earnings visibility and suggesting management expects recovery/growth later in the year. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Leadership change announced — Stuart Essig named next President & CEO and Michael McBreen appointed Chief Commercial Officer; this is material but the impact depends on execution and strategy under new leadership. Integra LifeSciences Announces Leadership Transition
• Neutral Sentiment: Investors can review management commentary and detail in the earnings call transcript and slide deck for product/segment color that could drive forward guidance revisions. Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q2 guidance came in below Street expectations — management gave Q2 EPS of $0.44–$0.52 (consensus ~$0.53) and revenue guidance $410–$425M (vs. ~$425.3M consensus), creating near‑term growth risk and the main reason for the muted/negative market reaction. Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say

Institutional Trading of Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at $25,000. Osaic Holdings Inc. increased its stake in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the period. Virtu Financial LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $124,000. Finally, Amundi raised its holdings in shares of Integra LifeSciences by 17,193.8% during the second quarter. Amundi now owns 11,068 shares of the life sciences company’s stock worth $150,000 after purchasing an additional 11,004 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.